Lv4
678 积分 2024-04-22 加入
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
1天前
已完结
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
1天前
已关闭
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
1天前
已完结
Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators
1天前
已完结
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective
1天前
已完结
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
1天前
已完结
The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis
16天前
已完结
Pembrolizumab in HER2-Positive Gastric Cancer
16天前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
